Francesco Borriello, MD, PhD, is Executive Director of Early-Stage Biology and Discovery Lead at Generate:Biomedicines, where he leads cross-functional teams translating AI-designed proteins into therapeutic candidates. Following postdoctoral work in immunology, infectious diseases and cell signaling at Harvard Medical School, Francesco joined Generate in 2021 as a senior scientist and has since advanced to his current leadership role.
Francesco oversees some of Generate’s highest-priority programs in infectious diseases and immunology, bridging computational design with preclinical development. He sets experimental direction, defines success criteria, and brings structure to complex environments, enabling aligned, high-consequence decisions across functions.
He played a central role in advancing GB-0895, an optimized anti-TSLP antibody now progressing toward late-stage clinical trials. The molecule combines improved potency and extended half-life to enable dosing to just twice per year instead of monthly—a shift that is anticipated to improve adherence and expand access for patients with chronic respiratory conditions. Francesco also led development of GB-0669, a therapeutic antibody for COVID-19 that targets the S2 stem helix—a region long considered undruggable—and demonstrated potent neutralization across all known sarbecovirus variants.
Beyond program leadership, Francesco is a trusted source of clarity, accountability, and alignment throughout the organization. He has helped shape how Generate executes at scale, emphasizing trust, discipline, and scientific rigor. His work has opened new possibilities for treating conditions once thought inaccessible and is helping set a new standard for translational speed and impact.